Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases

Kadimastem and Defymed Awarded Grant in the EU's Prestigious Eurostars Program for the Clinical Development of an Integrated Product for the Treatment of Diabetes

Nov. 12, 2018
The projected project budget is NIS 5.4 million for two years, with Kadimastem's share for the first year being NIS 1.5 million. The participation of the Innovation Authority will be at the rate of 50% of the Kadimastem budget.

FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS

Nov. 4, 2018
Ness Ziona, Israel, November 4, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that the US Food and Drug Administration (FDA) has granted AstroRx® for the treatment of ALS, orphan drug status in the United States.

Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:

Oct. 9, 2018
For the first time ever, the company has transplanted cells derived from embryonic stem cells in ALS patients

Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem

Oct. 2, 2018
The amount raised to enable the company to reach the significant milestone of product efficacy results for cohorts A and B in Phase I/IIa clinical trial in ALS

Kadimastem and The Australian Foundation for Diabetes Research (AFDR) Selected to Receive a bi-National Grant from the Australian Government and the Israel Innovation Authority to Explore a Combined Diabetes Solution

Jul. 2, 2018
The project budget is three million NIS, of which approximately one million NIS has been approved for the first year of activity.

Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial

Jul. 1, 2018
Ness Ziona, Israel, July 1st 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced that that it has upgraded the clean rooms, where the company's flagship product AstroRx® is manufactured.

Scientific Article by Kadimastem Regarding Its Cell-Based Treatment for ALS Published by a Prestigious Cell Therapy Scientific Journal

Jun. 6, 2018
The article describes the comprehensive scientific research of the company's flagship product, AstroRx®, which is the foundation of the clinical trial the company is currently conducting in ALS patients

Successful Public Offering for Kadimastem

May. 15, 2018
Raised NIS 2.8M at a Premium to the Market Price

Kadimastem Successfully Raised NIS 15.6M in Rights Offering

Dec. 17, 2017
Company stakeholders invested NIS 6.3M

A Vote of Confidence in Kadimastem: Senior Scientists from the Weizmann Institute Invest in the Company

Aug. 13, 2017
Prof. Ruth Arnon and Prof. Michel Revel to Invest NIS 720K in the Company

Kadimastem Controlling Shareholder to Invest NIS 3.5M by Way of Private Placement

Jul. 9, 2017
In the past month, stakeholders have invested in the company NIS 5.6M

2017 Innovation Authority Budget Approved for Kadimastem: NIS 12 M for ALS Project

Jun. 4, 2017
This is the largest budget for ALS that Kadimastem has received yet from the Innovation Authority (formerly Office of the Chief Scientist)

Success for Kadimastem in Rights Offering;

Feb. 28, 2017
Raised NIS 7.2M 71% of the rights offered were exercised

Kadimastem Announces Strategic Collaboration with Korean Biotech Company Corestem, Including a $7M Investment in Kadimastem

Dec. 7, 2016
Corestem is the only company in the world with a cell therapy treatment for ALS which has been approved for marketing by a regulatory authority. Corestem believes in Kadimastem's technologies in the ALS and diabetes fields, and the agreement will assist in expediting Kadimastem's entry into the market

Stakeholders' Support for Kadimastem Continues: Investment of NIS 2.5M by Way of Convertible Loan

Nov. 9, 2016
If an investment agreement of $ 2M or more will be signed with a foreign company or investor, the loan will be converted in a rights offering under identical terms

Towards the Company's First Clinical Trial;

Nov. 2, 2016
Kadimastem Signs Letter of Intent with Hadassah Medical Center for Performance of the Clinical Trial in ALS

Press Releases Archive